Details of the Drug

General Information of Drug (ID: DMNRYPF)

Drug Name
Cixutumumab
Synonyms LY3012217
Indication
Disease Entry ICD 11 Status REF
Liver cancer 2C12 Phase 2 [1]
Non-small-cell lung cancer 2C25.Y Phase 2 [1]
Drug Type
Monoclonal antibody
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 148 hours [2]
Cross-matching ID
DrugBank ID
DB12250
TTD ID
D0E5DP
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin-like growth factor I receptor (IGF1R) TTHRID2 IGF1R_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Liver cancer
ICD Disease Classification 2C12
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin-like growth factor I receptor (IGF1R) DTT IGF1R 1.64E-01 0.25 0.64
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01232452) A Study in Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 Jul;26(7):1459-64.